# KOMP2-Phase3 Production and Phenotyping by the DTCC Consortium.

> **NIH NIH UM1** · UNIVERSITY OF CALIFORNIA AT DAVIS · 2023 · $2,365,000

## Abstract

KOMP2-Phase3 Production and Phenotyping by the DTCC Consortium
 PROJECT SUMMARY/ABSTRACT
 This application will renew funding for our consortium (DTCC) to continue to participate in Phase3 of the NIH
Knockout Mouse Phenotyping Project (KOMP2). DTCC proposes to produce 600 null mutant mouse lines for
genes with little to no functional annotation or phenotype by electroporation of Cas9 RNA-guided nucleases into
1-cell stage C57BL/6N zygotes and upload all production data and information to the International Mouse
Phenotyping Consortium (IMPC)’s GenTaR database. DTCC will then generate age-matched and sex-balanced
cohorts of 600 mutant homozygous or heterozygous mouse lines and wildtype C57BL/6N control mice for
juvenile phenotyping in the Early Adult Pipeline and embryo phenotyping of homozygous nonviable mouse lines
in the Embryo Pipeline. We will use categorical and continuous tests and procedures standardized by the IMPC
and selected by balancing the breadth of phenotyping with a >4% abnormal phenotype hit rate across the IMPC
during KOMP-Phase2 to develop an informative multi-domain pipeline. After quality assurance of our processes
and quality control of our products, all data, metadata, and images will be available for upload to the Data
Coordination Center (DCC). After additional quality control at the DCC, our data will be transferred to the
Central Data Archive for statistical analysis and from there to the IMPC web portal for public access. All mutant
mouse lines will be available upon request by the research community as live mice while production and
phenotyping are in progress and thereafter as frozen germplasm and as live mice after cryorecovery from the
Mutant Mouse Resource and Research Center and Canadian Mouse Mutant Resource. Additional biological
resources (e.g., fixed tissue) will also be available through the web portal and all DTCC’s standardized
operating procedures, expertise, and advice are available by email or videoconference. To continuously adapt
and improve high-throughput design, production, and phenotyping, DTCC will conduct technology development
projects to increase efficiency of production (e.g., expanding the genome editing toolbox, generating landing-
pad alleles) and pilot phenotyping tests (e.g., automated home-cage monitoring, whole-body MRI) to assess
their utility, capability, cost-effectiveness, and informative value to the Early Adult and Embryo Pipelines. In
addition to prioritizing genes with a human ortholog and no or little functional annotation, DTCC will also
actively request the scientific community to nominate genes to produce and phenotype that have likely disease
associations.
 Grant-funded member centers of DTCC include the University of California Davis (UCD; lead institution) and
The Center for Phenogenomics (TCP; subcontractor) in Toronto, Canada. We propose to leverage our
extensive experience and continue to use and refine well-tested coordinated management, strategy, protocols,
and proce...

## Key facts

- **NIH application ID:** 10683314
- **Project number:** 5UM1OD023221-12
- **Recipient organization:** UNIVERSITY OF CALIFORNIA AT DAVIS
- **Principal Investigator:** KC KENT LLOYD
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $2,365,000
- **Award type:** 5
- **Project period:** 2011-09-16 → 2027-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10683314

## Citation

> US National Institutes of Health, RePORTER application 10683314, KOMP2-Phase3 Production and Phenotyping by the DTCC Consortium. (5UM1OD023221-12). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10683314. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*